The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of ...

Johnson & Johnson has been fighting thousands of lawsuits over its now-discontinued talc products for 16 years. A pending ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...